These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 3094444)

  • 21. RO 23-6240 (AM-833), a new fluoroquinolone: in vitro antimicrobial activity and tentative disk diffusion interpretive criteria.
    Fuchs PC; Jones RN; Barry AL; Ayers LW; Gavan TL; Gerlach EH; Thornsberry C
    Diagn Microbiol Infect Dis; 1987 May; 7(1):29-35. PubMed ID: 3121241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
    Barry AL; Fuchs PC
    Antimicrob Agents Chemother; 1991 May; 35(5):955-60. PubMed ID: 1906696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.
    Wise R; Andrews JM; Edwards LJ
    Antimicrob Agents Chemother; 1983 Apr; 23(4):559-64. PubMed ID: 6222695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of PD 117596-2, a broad-spectrum difluoroquinolone.
    Neu HC; Chin NX
    Eur J Clin Microbiol Infect Dis; 1989 Jul; 8(7):644-50. PubMed ID: 2506029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimicrobial activity of Ro 24-6778, a covalent bonding of desmethylfleroxacin and desacetylcefotaxime.
    Jones RN
    Diagn Microbiol Infect Dis; 1990; 13(3):253-9. PubMed ID: 2116952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
    Stamm JM; Hanson CW; Chu DT; Bailer R; Vojtko C; Fernandes PB
    Antimicrob Agents Chemother; 1986 Feb; 29(2):193-200. PubMed ID: 3087274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of BAY 12-8039, a new fluoroquinolone.
    Woodcock JM; Andrews JM; Boswell FJ; Brenwald NP; Wise R
    Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In-vitro activity of fleroxacin against urinary tract and genital tract pathogens.
    Dubois J; Fontaine V
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():31-4. PubMed ID: 3144546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of the tricyclic beta-lactam GV104326.
    Wise R; Andrews JM; Brenwald N
    Antimicrob Agents Chemother; 1996 May; 40(5):1248-53. PubMed ID: 8723475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparative in vitro activity of garenoxacin (BMS-284756). Sentry program, Spain (1999-2000)].
    Loza E; Cantón R; Pascual A; Tubau F; Morosini MI; Almaraz F; Perea E; Martín R; Jones RN; Baquero F
    Enferm Infecc Microbiol Clin; 2003 Oct; 21(8):404-9. PubMed ID: 14525705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of fleroxacin (Ro23-6240), a new fluorinated 4-quinolone against isolates from cancer patients.
    Rolston K; Ho DH; LeBlanc B; Bodey GP
    Chemotherapy; 1988; 34(6):448-54. PubMed ID: 3149568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro activity of PD 127,391, an enhanced-spectrum quinolone.
    Wise R; Ashby JP; Andrews JM
    Antimicrob Agents Chemother; 1988 Aug; 32(8):1251-6. PubMed ID: 3142350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents.
    Wise R; Andrews JM; Danks G
    J Antimicrob Chemother; 1984 Mar; 13(3):237-44. PubMed ID: 6586712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In-vitro activity of fleroxacin compared with three other quinolones.
    Bremner DA; Dickie AS; Singh KP
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():19-23. PubMed ID: 3144536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [In vitro antibacterial activity of ciprofloxacin against uropathogenic organisms].
    Allocati N; Catamo G; Cellini L
    Boll Soc Ital Biol Sper; 1984 Oct; 60(10):1927-33. PubMed ID: 6440583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative in vitro activity of a new fluorinated 4-quinolone, QA-241.
    Niu WW; Neu HC
    Diagn Microbiol Infect Dis; 1989; 12(3):243-51. PubMed ID: 2791486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative in vitro activity of Ro 09-1428, a novel cephalosporin with a catechol moiety.
    Qadri SM; Ayub A; Ueno Y; Saldin H
    Clin Ther; 1992; 14(4):562-9. PubMed ID: 1525790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In-vitro activity of fleroxacin.
    Georgopoulos A; Breyer S; Georgopoulos M; Mailer H; Graninger W
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():25-9. PubMed ID: 3144544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity and beta-lactamase stability of FK-037, a parenteral cephalosporin.
    Neu HC; Chin NX; Huang HB
    Antimicrob Agents Chemother; 1993 Mar; 37(3):566-73. PubMed ID: 8460925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1994)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Matsuda M; Tanimoto H; Nakata K; Nakamori Y; Kusano N
    Jpn J Antibiot; 1996 May; 49(5):419-55. PubMed ID: 8752860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.